Table IV.
Causes of death in relapsed or refractory AML patients treated with vosaroxin and cytarabine
| Cause of death | Deaths within 30 d/60 d per end of follow-up, n | ||||
|---|---|---|---|---|---|
| Schedule A* (n = 29) | Schedule B† (n = 35) | Schedule C72‡ (n = 29) | Schedule C90§ (n = 20) | All patients (N = 113) | |
| Disease progression | 1/4/17 | 3/10/23 | 0/2/25 | 1/3/15 | 5/19/80 |
| Pneumonia | 1/2/2 | 0 | 0 | 0/1/1 | 1/3/3 |
| Sepsis | 1/1/1 | 0 | 0 | 1/1/2 | 2/2/3 |
| Cardiac arrest | 0 | 0/0/1 | 0 | 0 | 0/0/1 |
| Cardiac failure | 1/1/1 | 0 | 0 | 0 | 1/1/1 |
| Cardiomyopathy | 0 | 0 | 1/1/1 | 0 | 1/1/1 |
| Colon perforation | 1/1/1 | 0 | 0 | 0 | 1/1/1 |
| Hepatorenal failure | 0/1/1 | 0 | 0 | 0 | 0/1/1 |
| Lung cancer | 0 | 0/0/1 | 0 | 0 | 0/0/1 |
| Myocardial infarction | 0 | 0 | 1/1/1 | 0 | 1/1/1 |
| Pulmonary haemorrhage | 0 | 0/1/1 | 0 | 0 | 0/1/1 |
| Respiratory failure | 0 | 0 | 0 | 0/1/1 | 0/1/1 |
| Subdural haemorrhage | 0 | 0/1/1 | 0 | 0 | 0/1/1 |
| Unknown | 0/1/2 | 0/1/4 | 0/1/1 | 0 | 0/3/7 |
AML, acute myeloid leukaemia.
*
72 mg/m2 on days 1, 8, and 15.
†
72 mg/m2 on days 1 and 8.
‡
72 mg/m2 on days 1 and 4.
§
90 mg/m2 on days 1 and 4.